Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic
Long‐term serious adverse events · patients with rheumatoid arthritis
1 finding from 1 review
- no estimate extracted2 studies · 950 participantsLow
Findings
What do systematic reviews say?
1,514 questions · 1,543 findings · 649 reviews
No studies found 224 · 14.5%GRADE not reported 105 · 6.8%Very low 383 · 24.8%Low 447 · 29%Moderate 293 · 19%High 91 · 5.9%
Intermittent/cyclic etidronate 400 mg/day vs placebo
Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes onlyRR 1.09 [0.54, 2.18]Studies not reportedVery low
Intermittent/cyclic etidronate 400 mg/day vs placebo
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes onlyRR 1.41 [0.81, 2.47]Studies not reportedLow
Intrauterine infusion/injection of autologous platelet‐rich plasma vs placebo or no intervention
Adverse events: ectopic pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes adverse events: ectopic pregnancy compared with no intervention or placebo (very low certainty).
1 finding from 1 review
- OR 2.94 [0.12, 73.95]1 study · 94 participantsVery low
PGD2R antagonist OC000459 vs placebo
Withdrawals due to adverse events · active EoE patients
1 finding from 1 review
- no estimate extracted1 study · 26 participantsVery low
Vitamin D vs placebo/no treatment
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
- RR 1.97 [0.18, 21.27]12 studies · 1251 participantsVery low
Infliximab 5–10 mg/kg vs placebo
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 2.5 [0.12, 50.54]1 study · 94 participantsVery low
Synbiotic vs placebo
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether synbiotic changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Probiotics for management of functional abdominal pain disorders in children 2023 · Cochrane Headline outcomes onlyRR 4.58 [0.8, 26.19]4 studies · 302 participantsVery low
Probiotics vs placebo
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether probiotic changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Probiotics for management of functional abdominal pain disorders in children 2023 · Cochrane Headline outcomes onlyRR 1 [0.07, 15.12]8 studies · 544 participantsVery low
Phosphodiesterase 5 inhibitors (PDE5i) vs placebo
Withdrawals due to adverse events · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
- Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedModerate
Spinal cord stimulation vs placebo
Withdrawals due to adverse events · adults with low back pain
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsVery low
Cannabis‐based medicines vs placebo medication
Withdrawals due to adverse events · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in withdrawals due to adverse events compared with placebo medication (moderate certainty).
1 finding from 1 review
- Cannabis‐based medicines and medical cannabis for adults with cancer pain 2023 · Cochrane Headline outcomes onlyRD 0.04 [0, 0.08]4 studies · 1332 participantsModerate
Risedronate 5 mg/day vs placebo
Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.98 [0.9, 1.07]Studies not reportedHigh
Risedronate 5 mg/day vs placebo
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.67 [0.38, 1.18]Studies not reportedLow
Antioxidants vs placebo or no treatment
Gastrointestinal adverse events · patients with male subfertility
Antioxidants may leads to higher adverse events ‐ Gastrointestinal compared with placebo or no treatment (low certainty).
1 finding from 1 review
- OR 2.7 [1.46, 4.99]16 studies · 1355 participantsLow
Drug treatment vs placebo or no treatment
Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
- no estimate extracted5 studies · 5 participantsVery low
Summary of findings table ‐ Adjunctive therapies in addition to land‐based exercise therapy vs placebo adjunctive therapies
Withdrawals due to adverse events · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
- Adjunctive therapies in addition to land‐based exercise therapy for osteoarthritis of the hip or knee 2022 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Summary of findings table ‐ Cannabis vs placebo
Number withdrawn due to adverse events · health problem or population
Summary of findings table ‐ Cannabis may leads to higher withdrawn due to adverse events ( compared with placebo (low certainty).
1 finding from 1 review
- Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes onlyOR 2.41 [1.51, 3.84]21 studies · 3110 participantsLow
Probiotics vs placebo
Withdrawals due to adverse events · children with Hirschsprung's disease (HD)
1 finding from 1 review
- Probiotics for the prevention of Hirschsprung‐associated enterocolitis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 60 participantsGRADE not reported
Antibiotics vs placebo
Withdrawals due to adverse events · people with active UC
Antibiotics showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes onlyRR 2.06 [0.27, 15.72]8 studies · 691 participantsLow